Loading... Please wait...
EUR
- Home
- In Vivo Antibodies
- Mouse In Vivo Antibodies
- Anti-Mouse CD40 In Vivo Antibody - Low Endotoxin (IVMB0152)
Product Description
| Product Name: | Anti-Mouse CD40 In Vivo Antibody - Low Endotoxin |
| Product Code: | IVMB0152 |
| Size: | 1mg, 5mg, 25mg, 50mg, 100mg |
| Clone: | FGK45 |
| Protein: | CD40 |
| Product Type: | Monoclonal Antibody |
| Synonyms: | Bp50, TNFRSF5 |
| Isotype: | Rat IgG2a |
| Reactivity: | Mouse |
| Immunogen: | Recombinant Mouse CD40 Fusion Protein |
| Applications: | Act, FA, FC |
| Formulation: | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Purity: | ≥95% monomer by analytical SEC >95% by SDS Page |
| Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Storage and Handling: | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Applications: | Act, FA, FC |
| Recommended Usage: | FC The suggested concentration for this FGK45 antibody for staining cells in flow cytometry is ≤ 1.0 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application. |
| Reactivity: | Mouse |
| Host Species: | Rat |
| Specificity: | Clone FGK45 recognizes an epitope on mouse CD40. |
| Antigen Distribution: | CD40 is widely expressed on antigen-presenting cells such as dendritic cells, B cells, macrophages, and monocytes, in addition to non-immune endothelial cells, basal epithelial cells, and a variety of tumors. |
| Immunogen: | Recombinant Mouse CD40 Fusion Protein |
| Concentration: | ≥ 5.0 mg/ml |
| Endotoxin Level: | < 1.0 EU/mg as determined by the LAL method |
| Purity: | ≥95% monomer by analytical SEC >95% by SDS Page |
| Formulation: | This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. |
| Preparation: | Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. |
| Storage and Handling: | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
CD40 is a 48 kD type I transmembrane glycoprotein that is a member of the TNFR superfamily. CD40, in association with its ligand CD154 (CD40L) - a 39 kD protein, acts as a costimulatory molecule for the activation of B cells, dendritic cells, monocytes, and other antigen presenting cells. CD40 is involved in Ig isotype switching and dendritic cell maturation, as well as the activation, differentiation and proliferation of B cells. CD40 interacts with TNFR2 and is involved in the regulation of signal transduction. CD40 is a potential target for cancer immunotherapy. Blocking the interaction of CD40 with its ligand (CD154) is the sought-after therapeutic objective for preventing and/or improving both autoimmune diseases and transplant rejection. Studies have shown that monoclonal antibodies that block CD154 in human clinical trials resulted in unanticipated vascular complications. Hence, an interest in the therapeutic potential for antagonist mAbs specific for human CD40 is emerging. Antibodies of particular therapeutic interest are those that do not inhibit CD40 signaling via physical competition with CD154. Additionally, the interaction of CD40 and its ligand (CD154) is found to be essential for amyloid-beta-induced microglial activation, thus plays a significant part in Alzheimer disease pathogenesis.
| Datasheet: | View |
| Protein: | CD40 |
| Ligand/Receptor: | CD154 |
| Research Area: | Cell Biology, Costimulatory Molecules, Immunology, Neuroscience, Neuroscience Cell Markers |
![Anti-Human CD40 [G28.5] In Vivo Antibody - Low Endotoxin](https://cdn11.bigcommerce.com/s-h68l9z2lnx/products/214348/images/569352/anti-human-cd40-g28.5-in-vivo-antibody-low-endotoxin__55086.1673496638.220.290.jpg?c=2)
![Anti-Mouse CD40 [FGK45] In Vivo Antibody - Ultra Low Endotoxin](https://cdn11.bigcommerce.com/s-h68l9z2lnx/products/214488/images/569508/anti-mouse-cd40-fgk45-in-vivo-antibody-ultra-low-endotoxin__78080.1770913002.220.290.jpg?c=2)
